Clinical and Translational Allergy (Jan 2023)

Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air® approach

  • Jean Bousquet,
  • Josep M. Anto,
  • Bernardo Sousa‐Pinto,
  • Wienczyslawa Czarlewski,
  • Anna Bedbrook,
  • Tari Haahtela,
  • Ludger Klimek,
  • Oliver Pfaar,
  • Piotr Kuna,
  • Maciej Kupczyk,
  • Frederico S. Regateiro,
  • Boleslaw Samolinski,
  • Arunas Valiulis,
  • Arzu Yorgancioglu,
  • Sylvie Arnavielhe,
  • Xavier Basagaña,
  • Karl C. Bergmann,
  • Sinthia Bosnic‐Anticevich,
  • Luisa Brussino,
  • G. Walter Canonica,
  • Victoria Cardona,
  • Lorenzo Cecchi,
  • Claudia Chaves‐Loureiro,
  • Elisio Costa,
  • Alvaro A. Cruz,
  • Bilun Gemicioglu,
  • Wytske J. Fokkens,
  • Juan Carlos Ivancevich,
  • Helga Kraxner,
  • Violeta Kvedariene,
  • Désirée E. Larenas‐Linnemann,
  • Daniel Laune,
  • Renaud Louis,
  • Michael Makris,
  • Marcus Maurer,
  • Erik Melén,
  • Yann Micheli,
  • Mario Morais‐Almeida,
  • Joaquim Mullol,
  • Marek Niedoszytko,
  • Yoshitaka Okamoto,
  • Nikolaos G. Papadopoulos,
  • Vincenzo Patella,
  • Nhân Pham‐Thi,
  • Philip W. Rouadi,
  • Joaquin Sastre,
  • Nicola Scichilone,
  • Aziz Sheikh,
  • Mikhail Sofiev,
  • Luis Taborda‐Barata,
  • Sanna Toppila‐Salmi,
  • Ioanna Tsiligianni,
  • Erkka Valovirta,
  • Maria Teresa Ventura,
  • Rafael José Vieira,
  • Mihaela Zidarn,
  • Rita Amaral,
  • Ignacio J. Ansotegui,
  • Annabelle Bédard,
  • Samuel Benveniste,
  • Michael Bewick,
  • Carsten Bindslev‐Jensen,
  • Hubert Blain,
  • Matteo Bonini,
  • Rodolphe Bourret,
  • Fulvio Braido,
  • Pedro Carreiro‐Martins,
  • Denis Charpin,
  • Ivan Cherrez‐Ojeda,
  • Tomas Chivato,
  • Derek K. Chu,
  • Cemal Cingi,
  • Stefano DelGiacco,
  • Frédéric deBlay,
  • Philippe Devillier,
  • Govert DeVries,
  • Maria Doulaptsi,
  • Virginie Doyen,
  • Gérard Dray,
  • Jean‐François Fontaine,
  • R. Maximiliano Gomez,
  • Jan Hagemann,
  • Enrico Heffler,
  • Maja Hofmann,
  • Ewa Jassem,
  • Marek Jutel,
  • Thomas Keil,
  • Vicky Kritikos,
  • Inger Kull,
  • Marek Kulus,
  • Olga Lourenço,
  • Eve Mathieu‐Dupas,
  • Enrica Menditto,
  • Ralph Mösges,
  • Ruth Murray,
  • Rachel Nadif,
  • Hugo Neffen,
  • Stefania Nicola,
  • Robyn O’Hehir,
  • Heidi Olze,
  • Yuliia Palamarchuk,
  • Jean‐Louis Pépin,
  • Benoit Pétré,
  • Robert Picard,
  • Constantinos Pitsios,
  • Francesca Puggioni,
  • Santiago Quirce,
  • Filip Raciborski,
  • Sietze Reitsma,
  • Nicolas Roche,
  • Monica Rodriguez‐Gonzalez,
  • Jan Romantowski,
  • Ana Sá‐Sousa,
  • Faradiba S. Serpa,
  • Marine Savouré,
  • Mohamed H. Shamji,
  • Milan Sova,
  • Annette Sperl,
  • Cristiana Stellato,
  • Ana Todo‐Bom,
  • Peter Valentin Tomazic,
  • Olivier Vandenplas,
  • Michiel VanEerd,
  • Tuula Vasankari,
  • Frédéric Viart,
  • Susan Waserman,
  • Joao A. Fonseca,
  • Torsten Zuberbier

DOI
https://doi.org/10.1002/clt2.12215
Journal volume & issue
Vol. 13, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract MASK‐air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK‐air® is a Good Practice of DG Santé on digitally‐enabled, patient‐centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co‐operation and Development). MASK‐air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK‐air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as‐needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom‐medication score (ARIA‐EAACI‐CSMS) has been validated for clinical practice and trials. The implications of the novel MASK‐air® results should lead to change management in rhinitis and asthma.

Keywords